Johnson & Johnson and Subsidiaries Reconciliation of Non-GAAP Financial Measures (Dollars in Millions Except Per Share Data) 2020 2019 2020 2019 Net Earnings, after tax- as reported $1,738 $4,010 $14,714 $15,119 Pre-tax Adjustments Intangible Asset Amortization expense 1,234 1,142 4,660 4,528 Litigation expense, net 2,902 264 5,112 5,096 IPR&D 37 - 181 890 Restructuring related 85 251 448 611 Acquisition and Integration related ¹ 14 90 (1,073) 319 Unrealized (gains)/losses on securities (373) (350) (547) (567) Medical Device Regulation 2 55 - 144 - Other - 13 6 20 Tax Adjustments Tax impact on special item adjustments 3 (606) (123) (1,608) (1,977) Tax legislation and other tax related (121) (270) (604) (729) Adjusted Net Earnings, after tax $4,965 $5,027 $21,433 $23,310 Average shares outstanding (Diluted) 2,669.2 2,669.1 2,670.7 2,684.3 Adjusted net earnings per share (Diluted) $1.86 $1.88 $8.03 $8.68 Operational adjusted net earnings per share (Diluted) $1.82 $8.00 Notes: 1 2 3 Prior year amounts have been reclassified to conform to current year disclosure Fourth Quarter Twelve Months Ended Acquisition and integration related costs for 2020 primarily includes a Contingent Consideration reversal of $1,148M related to the timing of certain developmental milestones associated with the Auris Health acquisition. European Medical Device Regulation (MDR) costs represent one-time compliance costs for the Company’s previously registered products. MDR is a replacement of the existing European Medical Devices Directive regulatory framework, and manufacturers of currently marketed medical devices are required to comply with EU MDR beginning in May 2021. The Company considers the adoption of EU MDR to be a significant one-time regulatory change and is not indicative of on- going operations. The Company has excluded only external third-party regulatory and consulting costs from its Medical Devices operating segments' measures of profit and loss used for making operating decisions and assessing performance. The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the above pre-tax special items in arriving at adjusted earnings. -- 1 of 6 -- Johnson & Johnson and Subsidiaries Reconciliation of Non-GAAP Financial Measure Consumer Health Pharmaceutical Medical Devices Total WW As Reported 1.4% 16.3% (0.7)% 8.3% U.S. 2.7% 15.3% 1.5% 9.6% International 0.5% 17.7% (2.6)% 7.0% WW Currency (0.6) 1.7 1.5 1.2 U.S. - - - - International (1.0) 4.2 2.9 2.7 WW Operational 2.0% 14.6% (2.2)% 7.1% U.S. 2.7% 15.3% 1.5% 9.6% International 1.5% 13.5% (5.5)% 4.3% General Surgery Advanced Sterilization Products 0.6 0.2 U.S. 0.0 0.0 International 1.0 0.4 All Other Acquisitions and Divestitures 0.1 0.0 0.1 0.1 U.S. 0.1 (0.1) 0.2 0.0 International 0.1 0.2 0.0 0.1 WW Adjusted Operational 2.1% 14.6% (1.5)% 7.3% U.S. 2.8% 15.2% 1.7% 9.6% International 1.6% 13.7% (4.4)% 4.8% Adjusted Operational Sales Growth FOURTH QUARTER 2020 ACTUAL vs. 2019 ACTUAL Segments Note: Percentages are based on actual, non-rounded figures and may not sum -- 2 of 6 -- Johnson & Johnson and Subsidiaries Reconciliation of Non-GAAP Financial Measure Consumer Health Pharmaceutical Medical Devices Total WW As Reported 1.1% 8.0% (11.6)% 0.6% U.S. 9.0% 7.8% (10.9)% 2.5% International (4.6)% 8.3% (12.2)% (1.3)% WW Currency (1.9) (0.2) (0.2) (0.6) U.S. - - - - International (3.3) (0.5) (0.4) (1.1) WW Operational 3.0% 8.2% (11.4)% 1.2% U.S. 9.0% 7.8% (10.9)% 2.5% International (1.3)% 8.8% (11.8)% (0.2)% Skin Health / Beauty Dr. Ci Labo - Japan (0.1) 0.0 U.S. 0.0 0.0 International (0.2) 0.0 General Surgery Advanced Sterilization Products 0.8 0.3 U.S. 0.6 0.2 International 1.0 0.4 Baby Care Baby Center 0.2 0.0 U.S. 0.5 0.1 International 0.0 0.0 All Other Acquisitions and Divestitures 0.0 0.2 0.0 0.1 U.S. 0.0 0.0 0.0 0.0 International (0.1) 0.3 0.0 0.1 WW Adjusted Operational 3.1% 8.4% (10.5)% 1.5% U.S. 9.5% 7.8% (10.2)% 2.8% International (1.5)% 9.1% (10.9)% 0.2% Adjusted Operational Sales Growth TWELVE MONTHS 2020 ACTUAL vs. 2019 ACTUAL Segments Note: Percentages are based on actual, non-rounded figures and may not sum -- 3 of 6 -- Johnson & Johnson and Subsidiaries Reconciliation of Non-GAAP Financial Measures 2020 2019 2020 2019 2020 2019 2020 2019 2020 2019 Reported Income/(Loss) Before Tax by Segment $ (2,057) 261 3,675 3,030 363 1,208 (334) (281) 1,647 4,218 % to Sales -56.9% 7.3% 30.0% 28.7% 5.5% 18.2% -1.5% -1.4% 7.3% 20.3% Intangible asset amortization expense 109 105 868 781 257 256 - - 1,234 1,142 In-process research and development - - 10 - 27 - - - 37 - Litigation, net 2,762 221 (172) 6 312 37 - - 2,902 264 Unrealized loss/(gain) on securities - - (368) (336) (5) (14) - - (373) (350) Restructuring related (1) 62 24 25 62 164 - - 85 251 Acquisition and integration related - - - 62 14 28 - - 14 90 Medical Device Regulation - - - - 55 - - - 55 - Other - - - - - 13 - - - 13 Adjusted Income Before Tax by Segment $ 813 649 4,037 3,568 1,085 1,692 (334) (281) 5,601 5,628 % to Sales 22.5% 18.2% 32.9% 33.8% 16.5% 25.5% -1.5% -1.4% 24.9% 27.1% *Estimated as of 1/26/2021. Q4 QTD - Income Before Tax by Segment* Dollars in Millions Consumer Health Pharmaceutical Medical Devices Unallocated Worldwide Total -- 4 of 6 -- Johnson & Johnson and Subsidiaries Reconciliation of Non-GAAP Financial Measures 2020 2019 2020 2019 2020 2019 2020 2019 2020 2019 Reported Income/(Loss) Before Tax by Segment $ (1,064) 2,061 15,462 8,816 3,044 7,286 (945) (835) 16,497 17,328 % to Sales -7.6% 14.8% 33.9% 20.9% 13.3% 28.1% -1.1% -1.0% 20.0% 21.1% Intangible asset amortization expense 415 392 3,246 3,151 999 985 - - 4,660 4,528 In-process research and development - - 10 890 171 - - - 181 890 Litigation expense, net 3,931 393 834 4,331 347 372 - - 5,112 5,096 Unrealized loss/(gain) on securities - (1) (545) (572) (2) 6 - - (547) (567) Restructuring related 68 123 94 93 286 395 - - 448 611 Acquisition and integration related - - 20 185 (1,093) 134 - - (1,073) 319 Medical Device Regulation - - - - 144 - - - 144 - Other - - - - 6 20 - - 6 20 Adjusted Income Before Tax by Segment $ 3,350 2,968 19,121 16,894 3,902 9,198 (945) (835) 25,428 28,225 % to Sales 23.8% 21.4% 42.0% 40.0% 17.0% 35.4% -1.1% -1.0% 30.8% 34.4% *Estimated as of 1/26/2021. Q4 YTD - Income Before Tax by Segment* Dollars in Millions Consumer Health Pharmaceutical Medical Devices Unallocated Worldwide Total -- 5 of 6 -- Fourth Quarter Fourth Quarter Jan. 3, 2021 GAAP Intangible asset amortization Litigation expense, net Restructuring related Acquisition related Medical Device Regulation Other Jan. 3, 2021 Non-GAAP Cost of products sold 7,814 $ (1,225) (20) (19) 6,550 Selling, marketing and admin expenses 6,457 (7) 6,450 Research and development expense 4,032 - (29) 4,003 Other (Income) / Expense 2,354 (9) (2,902) (5) (14) 373 - (203) In-process research and development 37 (37) - Restructuring 60 (60) - Provision for/(Benefit from) taxes on income (91) (46) 682 6 16 3 (66) 11 121 - 636 Net Earnings 1,738 1,280 2,220 31 69 11 (307) 44 (121) - 4,965 Fourth Quarter Fourth Quarter Dec. 29, 2019 GAAP Intangible asset amortization Litigation expense, net Restructuring related Acquisition related Medical Device Regulation Other Dec. 29, 2019 Non-GAAP Cost of products sold 7,134 $ (1,124) (70) 5,940 Research and development expense 3,232 (47) 3,185 Other (Income) / Expense 16 (18) (264) (77) (43) 350 (13) (49) Restructuring 104 (104) - Provision for taxes on income 208 134 13 37 8 (73) 270 4 601 Net Earnings 4,010 1,008 251 214 82 (277) (270) 9 5,027 Twelve Months Twelve Months Jan. 3, 2021 GAAP Intangible asset amortization Litigation expense, net Restructuring related Acquisition related (1) Medical Device Regulation Other Jan. 3, 2021 Non-GAAP Cost of products sold 28,427 $ (4,651) (89) (59) 23,628 Selling, marketing and admin expenses 22,084 (17) 22,067 Research and development expense 12,159 (68) 12,091 Other (Income) / Expense 2,899 (9) (5,112) (112) 1,073 547 (6) (720) In-process research and development 181 (181) - Restructuring 247 (247) - Provision for taxes on income 1,783 504 1,055 36 81 13 (108) 27 604 - 3,995 Net Earnings 14,714 4,156 4,057 145 367 (1,086) (439) 117 (604) 6 21,433 Twelve Months Twelve Months Dec. 29, 2019 GAAP Intangible asset amortization Litigation expense, net Restructuring related Acquisition related Medical Device Regulation Other Dec. 29, 2019 Non-GAAP Cost of products sold 27,556 $ (4,472) (151) 22,933 Research and development expense 11,355 (47) 11,308 Other (Income) / Expense 2,525 (56) (5,096) (194) (272) 567 (20) (2,546) In-process research and development 890 (890) - Restructuring 266 (266) - Provision for taxes on income 2,209 684 1,081 187 100 39 (119) 729 5 4,915 Net Earnings 15,119 3,844 4,015 703 511 280 (448) (729) 15 23,310 (1) Primarily includes a Contingent Consideration reversal of $1,148M related to the timing of certain developmental milestones associated with the Auris Health acquisition. Prior year amounts have been reclassified to conform to current year presentation Johnson & Johnson and Subsidiaries GAAP to Non-GAAP Reconciliation $ in Millions Quarter to Date In-process research and development Unrealized (loss)/gain on securities Tax legislation and other tax related In-process research and development Unrealized (loss)/gain on securities Tax legislation and other tax related In-process research and development Unrealized (loss)/gain on securities Tax legislation and other tax related Year to Date In-process research and development Unrealized (loss)/gain on securities Tax legislation and other tax related -- 6 of 6 --